Posted: Friday, December 24, 2021. 11:20 am CST.
By Benjamin Flowers: This week, health authorities in the United States approved the use of molnupiravir, an antiviral drug manufactured by Merck & Co used to treat COVID-19 for certain adult patients, Reuters reports.
On Thursday, the U.S. Food and Drug Administration (FDA) approved the use of molnupiravir to treat mild-to-moderate COVID-19 in adults who are at high risk for severe disease, and for those whom alternative COVID-19 treatments may either be inaccessible or clinically appropriate. Mlnupiravir, which was developed with Ridgeback Biotherapeutics, was shown to reduce hospitalizations and deaths by around 30 percent in a clinical trial of high-risk individuals early in the course of the illness.
The drug is meant to be taken twice a day – four pills each time – for five days, making a full treatment course of 40 pills.
The FDA said that molnupiravir is not approved for patients below the age of 18 may affect bone and cartilage growth. The pill is also not recommended for use during pregnancy, the agency added.
Merck’s head of global public policy, Paul Schaper, in an interview with Reuters said that the company will ship hundreds of thousands of units of molnupiravir within several days and millions of courses of treatment within several weeks in the United States.
“We have entered into agreements with the US government for slightly more than 3 million doses, 3 million courses of treatment over 2021 and 2022,” Schaper told Reuters.
The FDA’s approval of molnupiravir comes the day after a similar but reportedly more effective drug manufactured by Pfizer Inc.
The U.S. has reportedly contracted Pfizer for 10 million courses of its drug at a price of $530 per course, as well as a deal with Merck for as many as 5 million courses of molnupiravir at a price of $700 per course.
Аdvеrtіѕе wіth thе most visited news site in Веlіzе ~ Wе оffеr fullу сuѕtоmіzаblе аnd flехіblе dіgіtаl mаrkеtіng расkаgеѕ. Yоur соntеnt іѕ dеlіvеrеd іnѕtаntlу tо thоuѕаndѕ оf uѕеrѕ іn Веlіzе аnd аbrоаd! Соntасt uѕ аt firstname.lastname@example.org оr саll uѕ аt 501-601-0315.
© 2021, BreakingBelizeNews.com. This article is the copyrighted property of Breaking Belize News. Written permission must be obtained before reprint in online or print media. REPRINTING CONTENT WITHOUT PERMISSION AND/OR PAYMENT IS THEFT AND PUNISHABLE BY LAW.